Breaking Down SG&A Expenses: United Therapeutics Corporation vs Rhythm Pharmaceuticals, Inc.

SG&A Expenses: United Therapeutics vs. Rhythm Pharmaceuticals

__timestampRhythm Pharmaceuticals, Inc.United Therapeutics Corporation
Wednesday, January 1, 20141213000381287000
Thursday, January 1, 20153425000452612000
Friday, January 1, 20166311000316800000
Sunday, January 1, 20179518000330100000
Monday, January 1, 201828080000265800000
Tuesday, January 1, 201936550000336200000
Wednesday, January 1, 202046125000423900000
Friday, January 1, 202168486000467000000
Saturday, January 1, 202292032000487000000
Sunday, January 1, 2023117532000477100000
Loading chart...

Unleashing insights

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and growth. This analysis compares the SG&A expenses of United Therapeutics Corporation and Rhythm Pharmaceuticals, Inc. from 2014 to 2023. Over this period, United Therapeutics consistently reported higher SG&A expenses, peaking at approximately $487 million in 2022. In contrast, Rhythm Pharmaceuticals saw a dramatic increase, with expenses rising from just over $1 million in 2014 to nearly $118 million by 2023, marking a staggering growth of over 9,600%. This trend highlights the aggressive expansion and scaling efforts by Rhythm Pharmaceuticals. Meanwhile, United Therapeutics' expenses remained relatively stable, reflecting a mature operational strategy. Understanding these financial dynamics offers valuable insights into each company's strategic priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025